Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years

Eline H. Ploumen, Martijn J. Oude Wolcherink, Rosaly A. Buiten, Tineke H. Pinxterhuis, Carine J. M. Doggen, Carl E. Schotborgh, Peter W. Danse, Martijn Scholte, K. Gert Houwelingen, Paolo Zocca, Xavier G. L. V. Pouwels and Clemens Birgelen ()
Additional contact information
Eline H. Ploumen: Thoraxcentrum Twente, Medisch Spectrum Twente
Martijn J. Oude Wolcherink: University of Twente
Rosaly A. Buiten: Thoraxcentrum Twente, Medisch Spectrum Twente
Tineke H. Pinxterhuis: Thoraxcentrum Twente, Medisch Spectrum Twente
Carine J. M. Doggen: University of Twente
Carl E. Schotborgh: Haga Hospital
Peter W. Danse: Rijnstate Hospital
Martijn Scholte: Albert Schweitzer Hospital
K. Gert Houwelingen: Thoraxcentrum Twente, Medisch Spectrum Twente
Paolo Zocca: Thoraxcentrum Twente, Medisch Spectrum Twente
Xavier G. L. V. Pouwels: University of Twente
Clemens Birgelen: Thoraxcentrum Twente, Medisch Spectrum Twente

PharmacoEconomics - Open, 2025, vol. 9, issue 1, No 13, 137-145

Abstract: Abstract Background and Objective Evidence on health economic outcomes for percutaneous coronary intervention (PCI) comparing different contemporary drug-eluting stents (DES) with each other is scarce, as most previous randomised DES trials did not assess such aspects. This prespecified health economic evaluation of the Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population (BIO-RESORT) trial aimed to compare at 3-year follow-up both health effects and costs of PCI with one of three new-generation drug-eluting stents (DES) in patients with obstructive coronary artery disease. Methods The randomised BIO-RESORT trial assessed in 3514 patients the ultrathin-strut biodegradable polymer Orsiro sirolimus-eluting stent (SES) and very-thin-strut Synergy everolimus-eluting (EES) stent versus the thin-strut durable polymer Resolute Integrity zotarolimus-eluting stent (ZES). In the current analysis, we used the perspective of a health insurer in the Netherlands. The main endpoints were quality-adjusted life years (QALYs), and costs for each treatment strategy. Bootstrapping with 5000 resamples was performed to capture the uncertainty of results. Results Mean QALYs for each stent group were 2.566 for the SES, 2.551 for the EES, and 2.550 for the ZES. Mean costs per strategy were €14,670 for the SES, €14,946 for the EES, and €15,069 for the ZES. The SES had the highest probability of being cost-effective for every willingness-to-pay threshold up to €100,000 per QALY. Furthermore, in 79% of modelling scenarios, the SES was more effective and cheaper than ZES. Conclusion At 3-year follow-up, PCI with the SES had the highest probability of being cost-effective due to greater effectiveness and lower costs compared with the ZES and EES. These findings suggest that, due to the overall high volume of coronary stenting in clinical practice, use of this SES could result in substantial cost savings, complemented by slight additional health benefits.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00539-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:1:d:10.1007_s41669-024-00539-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00539-x

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().